Apremilast (CC-10004) is an oral phosphodiesterase 4 inhibitor. The Ki-value (affinity constant) of apremilast for PDE4 is 68 nM. Apremilast binds to the catalytic site of the PDE4 enzyme, thereby blocking cAMP degradation. Apremilast (CC-10004) inhibits the production of TNF-α (IC50 = 0.11 μ), IFN-γ (IC50 = 0.013μ), and IL-12p70 (IC50 = 0.12 μ), as well as the chemokines CXCL9 (MIG), CXCL10 (IP-10), and CCL4 (MIP1a) from human peripheral blood mononuclear cells. In addition, apremilast inhibited N-formyl-Met-Leu-Phe-induced CD18 and CD11b expression leading to impaired adhesion of polymorphonuclear cells (PMN) to human umbilical vein endothelial cells. Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types. Apremilast also interferes with the production of leukotriene B4, inducible nitric oxide synthase, and matrix metalloproteinase and reduces complex inflammatory processes, such as dendritic cell infiltration, epidermal skin thickening, and joint destruction. Treatment with apremilast at a dosage of 20 mg twice per day or 40 mg once per day demonstrated efficacy in comparison with placebo and was generally well tolerated in patients with active PsA. Apremilast is currently in phase III trials.
Bioengineered. 2021 Dec;12(1):8583-8593.
Apremilast mitigates interleukin (IL)-13-induced inflammatory response and mucin production in human nasal epithelial cells (hNECs)
Apremilast purchased from AbMole
Molecular Weight | 460.5 |
Formula | C22H24N2O7S |
CAS Number | 608141-41-9 |
Solubility (25°C) | DMSO 62 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related PDE Products |
---|
ME-3183
ME-3183 is an oral selective PDE4 inhibitor with anti-inflammatory activity for studies related to plaque psoriasis. |
ART-648
ART-648 is a PDE4 inhibitor that may be used in studies related to non-alcoholic steatohepatitis. |
(E/Z)-HA155
(E/Z)-HA155 is a potent Autotaxin (ATX) type I inhibitor for studies related to cancer, fibrous disorders, inflammation, pain and angiogenesis. |
Autotaxin-IN-3
Autotaxin-IN-3 is an Autotaxin(ATX) inhibitor with an IC50 value of 2.4 nM. |
HA155
HA155 is a potent and selective ATX inhibitor with an IC50 value of 5.7 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.